Study Data: Amarantus One Step Closer to a Q4 Launch of an Alzheimer's Blood Test

Posted by Laura Swartz

October 10, 2014 at 2:28 PM

Amarantus-BioScience-Holdings-Logo-CroppedBiotech company Amarantus Bioscience Holdings, Inc. (AMBS-OTC) has reported positive data from its LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD). LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls. As a result of these positive findings, Amarantus is expanding the study to assess LymPro's predictive value in diagnosing early-stage AD patients. Amarantus anticipates launching LymPro in the fourth quarter of 2014.

Study Result Highlights

In a 72-subject study, including 36 patients with moderate-to-severe AD versus a control group of 36 healthy subjects, the expression of the marker CD69 on specific sub-populations of lymphocytic cells was statistically significantly lower in the AD groups versus the control group, as measured under two different stimulation conditions (LymPro Version 1 and LymPro Version 2).

CD69 is a protein expressed when lymphocytic blood cells are in the process of proliferating, and is considered an early marker that cell division is imminent. Low levels of CD69 under cell division conditions in AD patients is suggestive of lymphocytic cell cycle dysregulation and a surrogate marker for the neuronal cell cycle dysregulation that has been observed in the brains of AD patients at autopsy. Cell cycle dysregulation has been identified as a potential link between amyloid beta plaques and tau tangles in AD.

In Version 1, LymPro correctly classified AD patients and healthy controls with an overall accuracy of 87% (p=0.0015), with a high degree of sensitivity (80%) and specificity (86%). In Version 2, LymPro correctly classified AD patients and healthy controls with an overall accuracy of 83% (p=.0059) while maintaining a high degree of sensitivity (90%) and specificity (71%). The range of variations observed in sensitivity and specificity between LymPro Version 1 and LymPro Version 2 are common findings in diagnostic testing in heterogeneous indications such as Alzheimer's. Of particular importance is the consistency of the overall accuracy between Version 1 and Version 2. Further, the expression of CD69 did not change with disease severity, which is consistent with previous work suggesting that LymPro is measuring a fundamental stage-independent biology in AD patients.

Amarantus believes the results from both Version 1 and Version 2 of LymPro are suitable for commercialization, and is validating both Version 1 and Version 2 for use in the Research Use Only (RUO) market. Amarantus plans to launch LymPro for RUO in the fourth quarter of 2014, primarily targeting pharmaceutical clinical trials. The company does not require Clinical Laboratory Improvement Amendments (CLIA) certification to launch LymPro in the RUO market.

Colin Bier, PhD, member of the Amarantus Board of Advisors who is tasked with the development of LymPro, stated in the company's press release of these results that 

"LymPro will have great utility to the pharmaceutical companies developing drugs for Alzheimer's disease, as it will permit a more reliable way of selecting subjects for inclusion in trials, thereby assuring an enriched population and mitigating the risk of including non-Alzheimer's disease subjects."

Based on the strength of these results, the company has expanded the inclusion criteria to also enroll patients diagnosed with mild Alzheimer's disease. 68 additional subjects will be recruited, including 34 mild-to-severe Alzheimer's patients, and 34 healthy controls. Amarantus anticipates completing enrollment of the 68 patient LP-002 extension in the fourth quarter and will announce data from an in-depth analysis from the full cohort of 140 subjects (72 patients + 68 patient extension) shortly thereafter.

"Amarantus is aiming to be first to market with an accurate, reliable and commercially-viable diagnostic blood test for Alzheimer's disease," said Gerald E. Commissiong. "Today's data gives us all the information we need to move full steam ahead with this strategy. We can now tailor our initial marketing efforts towards the $150M RUO market, primarily targeting pharmaceutical companies engaged in Alzheimer's disease therapeutic trials. We have nearly completed assembling the resources needed to launch LymPro to the RUO community in the fourth quarter. Thereafter, we intend to market LymPro to the broader medical community, initially under CLIA. We estimate the worldwide market for an Alzheimer's diagnostic is $3B."

The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects. The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace.

*******************************************
Visit our Corporate Profile and Key Points pages for more
information, including the latest research and headlines,
on Amarantus BioScience Holdings, Inc. (AMBS-OTC).
*******************************************

Topics: Amarantus

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic